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Case Report

Eculizumab Dosing in Infants
Abstract

Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS).
Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and
one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise
dosing recommendations in children, particularly in infants, and for smaller vials of the medication
to facilitate more precise dosing. Such changes would ensure that adverse events are minimized
and that the children with aHUS who are treated with eculizumab experience an optimal clinical
response.
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Introduction
Atypical hemolytic uremic syndrome
(aHUS)
is
an
immune
disorder
stemming from dysregulation of the
alternative complement pathway, leading
to
complement
overactivation.
The
disease presents as a combination of
thrombotic
microangiopathy
(TMA),
thrombocytopenia, and renal failure.
Although rare with an estimated prevalence
of approximately 0.11 new cases/million
population/year,[1,2] it has a very high
mortality and morbidity that extends far
beyond the initial presentation period.[3] The
approval of eculizumab (Soliris, Alexion
Pharmaceuticals, Inc., Cheshire, CT,
USA) on September 23, 2011, as an
orphan drug marked a breakthrough for
this condition, as it was the first Food and
Drug Administration‑approved treatment
for aHUS; an untreatable disease suddenly
became treatable. International guidelines
place eculizumab as a first‑line treatment
in patients with a clinical diagnosis of
aHUS (confirmation of a complement
mutation is not required) that should
be initiated within 24–48 h of onset or
admission.[4] This quick initiation is to
achieve the best outcome with regard to
ultimate renal recovery and to diminish
the risk of early progression to end‑stage
renal disease.[5‑7] However, its dosing
presents a problem in pediatrics. The
current dosing recommendations on the
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eculizumab product label[8,9] are weight
based in increments of 5 kg and then
10 kg: 5–9.9 kg, 10–19.9 kg, 20–29.9 kg,
30–39.9 kg, and 40 kg and over. The
approval for the aHUS indication in
children was originally made based on one
retrospective chart review study outside
of a controlled clinical trial setting in
19 children under the age of 18 years, with
15 of those under the age of 12 years of
age and 5 under 2 years of age.[10,11]
One prospective pediatric study has been
published since eculizumab was approved
by the major regulatory agencies to treat
aHUS; the intent‑to‑treat population of this
study was 22, while only 19 completed
26 weeks of treatment. Of these children,
only one was younger than 1 year of
age (personal communication), five were
below 2 years of age, and 18 were below
12 years of age.[12] The composition of
both of these study cohorts suggests that
the dosing for children, particularly for
newborns, infants, and toddlers, was
extrapolated from a handful of patients.
Since this period brings rapid changes in
growth and ontogeny in drug disposition,
pediatric dosing recommendations must
be exact, and medications for children
are typically dosed either per kilogram of
body weight or per m2 of the child’s body
surface area (BSA) rather than in vague
weight increments. We detail the case of
the youngest patient in Canada with aHUS
to be treated with eculizumab and describe
the associated dosing challenges.

M. Kobrzynski1,
B. Wile1,
S. S. Huang2,
G. Filler1,3,4
Departments of 1Pediatrics and
3
Pathology and Laboratory
Medicine, Schulich School
of Medicine and Dentistry,
Western University, 2Department
of Medicine, Division of
Nephrology, Schulich School
of Medicine and Dentistry,
Western University, 4Department
of Children’s Health and
Therapeutics, Children’s Health
Research Institute, London, ON,
Canada

Address for correspondence:
Dr. G. Filler,
Department of Pediatrics,
Children’s Hospital ‑ London
Health Sciences Centre,
University of Western Ontario,
800 Commissioner’s Road
East, Rm B1‑138A, London,
ON N6A 5W9, Canada.
E‑mail: guido.filler@lhsc.on.ca

Access this article online
Website: www.indianjnephrol.org
DOI: 10.4103/ijn.IJN_310_16
Quick Response Code:

How to cite this article: Kobrzynski M, Wile B,
Huang SS, Filler G. Eculizumab dosing in infants.
Indian J Nephrol 2018;28:73-5.

© 2018 Indian Journal of Nephrology | Published by Wolters Kluwer - Medknow

73

[Downloaded free from http://www.indianjnephrol.org on Wednesday, February 14, 2018, IP: 202.177.173.189]
Kobrzynski, et al.: Eculizumab in pediatrics

Case Report
An 8‑month‑old previously healthy, fully immunized,
formula‑fed female presented to the emergency room
with a short history of an upper respiratory tract
infection (confirmed respiratory syncytial virus), feeding
intolerance, emesis (nonbilious and nonbloody), reduced
urine output, no diarrhea, and no contact with farm animals
or cow milk products. One day after her admission,
while afebrile, she was somnolent, pale, had slight
jaundice, and mild dehydration. Her urine output did not
improve following rehydration. She was transferred to
a tertiary care center, where testing revealed the blood
parameter levels as shown in Table 1.
Based on these results, she was diagnosed with systemic
TMA.
Her urinary sediment was very active. Her ADAMTS 13
(a disintegrin and metalloproteinase with a thrombospondin
Type 1 motif, member 13) activity was >69% (reference
interval 41%–130%), ruling out thrombocytopenic
purpura, and her stool was negative for Escherichia
coli O157: H7, ruling out Shiga toxin‑producing
E. coli‑HUS. The differential diagnosis was therefore
aHUS. Her complement C3 activity was normal, but
her CH50 activity was undetectable. The genetic
workup confirmed the presence of a pathogenic variant
(c.3546G>C [Arg1182Ser]) and of a variant of uncertain
significance (C.3148A>T [Asn1050Tyr]) in the complement
factor H (CFH) gene (laboratory of Dr. Christoph Licht,
Hospital for Sick Children, Toronto, Canada), while there
were no anti‑CFH antibodies. Treatment consisted of
plasma infusion therapy (up to 55 ml/FFP/kg) and four
treatments with plasma exchange with up to 1.5 times
of the patient’s plasma volume. She also received two
blood transfusions. Platelets, urine output, and creatinine
normalized. No steroids or other agents were given. Three
weeks later, she relapsed in association with an upper
respiratory tract infection. As there was no antibody titer
detectable at initial presentation, this was not reevaluated.
At this time, her hemoglobin dropped to 67 g/L, her
platelets dropped to 52 × 109/L, lactate dehydrogenase
rose to 1266 U/L, haptoglobin was undetectable, and she
required three transfusions. After receiving a meningococcal

conjugate vaccine, she was started on eculizumab, in
accordance with the consensus guidelines. With a weight
of 9.17 kg, she was initially given one 300 mg dose for
the 1st week of induction, then 300 mg 1 week later and
300 mg every 3 weeks during the maintenance phase,
as per the manufacturer’s instructions. Her platelet
count normalized after the first two treatments and her
haptoglobin normalized after 14 weeks. Interestingly, the
patient would experience feeding intolerance and vomiting
on day 16 following each treatment. Treatment was
accelerated to 18‑day and then 17‑day intervals without any
improvement in her day 16 symptoms; the dosing interval
was therefore shortened to 14 days. Finally, the patient’s
vomiting subsided with 14‑day treatment intervals, and for
the first time, after not having gained any weight from the
time of presentation, she gained some weight to 9.4 kg
following the first 14‑day treatment interval. Her weight
dropped from the 92nd to the 52nd percentile. Her CH50
complement activity remained undetectable. The results
of tests to measure eculizumab concentration are currently
pending. Her cystatin C estimated glomerular filtration
rate remains abnormal at 71 ml/min 1.73 m2 following
8 months of therapy [Figure 1].

Discussion
Great strides have been made within the last 15 years in
understanding the pathophysiology of aHUS, and scientists
are still elucidating the genetic background of this disease
by continuing to identify new genetic mutations associated
with aHUS. The publication of comprehensive international
guidelines for diagnosing and treating pediatric aHUS in
January of 2016 in Pediatric Nephrology[4] also represents a
significant advancement in physicians’ abilities to properly
diagnose aHUS in children. Since, until very recently, an
aHUS diagnosis entailed a grim outlook and often death,
new guidelines and a new treatment will most likely result
in a greater number of diagnoses that will be made more
quickly and will be more accurate. In the prospective
pediatric eculizumab trial by Greenbaum et al.,[12] a post hoc

Table 1: Blood parameter results at presentation

Blood parameters at presentation
Result
Reference Condition
interval
Platelet count
48×109/L 150‑400×109/L Thrombocytopenia
Hemoglobin
60 (g/L)
100‑140 (g/L) Hemolytic anemia
Lactate
4909 (U/L)
<300 (U/L)
dehydrogenase
Haptoglobin
Undetectable 0.26‑2.26 (g/L)
Serum creatinine 47 (µmol/L) <33 (µmol/L) Impaired renal
function
Parameter
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Figure 1: Chronological cystatin C estimated glomerular filtration rate and
haptoglobin measurements from the time of admission. Vomiting is marked
according to its duration and eculizumab treatments are marked with arrows
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analysis examining the children who did and did not meet
criteria for the primary endpoint at 26 weeks, which was
defined as a complete TMA response, revealed a stark
difference in the median age at first infusion. The median
age at first infusion of children who achieved the primary
endpoint was 7.5 years, while the median age of those
who did not was 2.0 years. This suggests that the younger
children tended to be underdosed and that eculizumab has
a shorter half‑life in children, so they were less likely to
achieve the primary endpoint when dosed according to
the current guidelines. This case study, where eculizumab
dosing in the <10 kg weight category was empirically
escalated, eventually resulting in a clinical remission,
highlights the need for more infant data to refine the current
pediatric eculizumab dosing guidelines. With the likelihood
that the identified prevalence of aHUS will increase in the
coming years, it is important to refine eculizumab dosing
in children, particularly in younger children. In addition
to recruiting more patients and collecting more data to
establish more precise dosing per kilogram of body weight
or per m2 of BSA, smaller vials should be produced to
implement more accurate dosing. Vials of 50 mg, 100 mg,
or even 150 mg would be highly beneficial to clinicians.
In the absence of additional pediatric pharmacokinetic
studies and precise guidelines, physicians should observe
the patient’s clinical response and adjust the patient’s dose
to minimize any adverse effects. The clinician should also
employ pharmacokinetic monitoring if the patient’s clinical
response is insufficient and adjust the dose accordingly.
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